Imunon, Inc. (NASDAQ:IMNN), a company operating in the biotechnology sector, is part of key market indexes such as the Top ...

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) stands against other firms that led last week’s charge. Biotechnology company Imunon Inc. soared by 114.6 percent ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

Imnn Stock- Imunon’s stock surged 179% after positive Phase 2 ovarian cancer trial results and plans for a Phase 3 study ...

Imunon (IMNN) stock rocketed higher on Friday after the pharmaceutical company announced positive results from its Phase 2 OVATION 2 Study of IMNN-001. This study was focused on using IMNN-001 as a ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.